Moreover, the 36-month beta value for BGLC is 1.65.
The public float for BGLC is 12.11M and currently, short sellers hold a 3.07% of that float. On March 06, 2025, BGLC’s average trading volume was 3.79M shares.
BGLC) stock’s latest price update
The stock of BioNexus Gene Lab Corp (NASDAQ: BGLC) has increased by 5.80 when compared to last closing price of 0.34. Despite this, the company has experienced a 7.85% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-05 that KUALA LUMPUR, Malaysia, March 06, 2025 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company’s new Ethereum-focused treasury strategy. This decision marks BGLC as the first Nasdaq-listed company to exclusively prioritize Ethereum (ETH) as a strategic treasury asset, and is in line with recent announcements of Ethereum being included in the US “Crypto Strategic Reserve”.
BGLC’s Market Performance
BioNexus Gene Lab Corp (BGLC) has experienced a 7.85% rise in stock performance for the past week, with a -10.32% drop in the past month, and a 3.26% rise in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 7.25% for BGLC. The simple moving average for the last 20 days is 1.14% for BGLC stock, with a simple moving average of -9.74% for the last 200 days.
BGLC Trading at 2.68% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.86% of loss for the given period.
Volatility was left at 7.25%, however, over the last 30 days, the volatility rate increased by 11.20%, as shares sank -7.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.83% upper at present.
During the last 5 trading sessions, BGLC rose by +4.83%, which changed the moving average for the period of 200-days by -38.37% in comparison to the 20-day moving average, which settled at $0.3568. In addition, BioNexus Gene Lab Corp saw 29.21% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.13 for the gross margin
The net margin for BioNexus Gene Lab Corp stands at -0.1. The total capital return value is set at -0.12. Equity return is now at value -9.87, with -8.38 for asset returns.
Based on BioNexus Gene Lab Corp (BGLC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.71. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -56.5.
Currently, EBITDA for the company is -2.49 million with net debt to EBITDA at 5.14. When we switch over and look at the enterprise to sales, we see a ratio of 0.26. The receivables turnover for the company is 6.12for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To wrap up, the performance of BioNexus Gene Lab Corp (BGLC) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
